Medtronic, a medical technology company headquartered in Dublin, Ireland with its diabetic care division in Northridge, has filed an application with the Food and Drug Administration, seeking approval to change the labeling for its MiniMed insulin pump system. According to a statement from the company on Tuesday, this type of labeling indicates that the pump sensor is accurate enough to safely and consistently calculate insulin doses for meals and correct high blood sugar levels. The patient wouldn’t need to use a finger stick while administering insulin because of the pump system’s accuracy. If the labeling is approved, Medtronic will be able to broaden patient access to the MiniMed pump. Medicare requires this labeling for sensor reimbursement.
